China NMPA Drug Inspection - Lanzhou Xukang Pharmaceutical Co., Ltd. - Platycodon grandiflorus

The Ningxia Drug Sampling Inspection Information Announcement (No. 09, 2018), published on August 17, 2018, reports on recent drug quality sampling inspections conducted in the Ningxia region of China. The inspections covered a broad range of pharmaceutical products from numerous manufacturers and distribution points, including pharmacies and hospitals. A total of 96 batches across 19 varieties were tested, encompassing chemical drugs, traditional Chinese medicine preparations, and traditional Chinese medicine decoction pieces.

The regulatory framework for these inspections included the "Drug Administration Law of the People's Republic of China," the "Regulations on the Administration of Drug Quality Sampling Inspection," the "Chinese Pharmacopoeia (2015 Edition, Parts I and II)," and various national and regional drug standards, such as the "Ningxia Traditional Chinese Medicine Piece Processing Specifications (2017 Edition)."

Crucially, the announcement confirms that all inspected drugs were found to be fully compliant with the applicable regulatory standards and specifications. Consequently, no main violations or issues were identified for any of the tested batches or their respective manufacturers and distributors. As a result, no specific corrective or required actions were mandated in this announcement for any company, as all products met the established quality and safety requirements.